<?xml version="1.0" encoding="UTF-8"?>
<p>In recent years, although the peptide antivirals have gained more attention, there are still a couple of hurdles to surmount before the clinical use (
 <xref rid="B7" ref-type="bibr">Boto et al., 2018</xref>; 
 <xref rid="B8" ref-type="bibr">Bruzzoni-Giovanelli et al., 2018</xref>). Currently, much progress has been made in designing artificial anti-ZIKV peptides (
 <xref rid="B48" ref-type="bibr">Yu et al., 2017</xref>; 
 <xref rid="B20" ref-type="bibr">He et al., 2018</xref>; 
 <xref rid="B34" ref-type="bibr">Si et al., 2019</xref>). On the other hand, natural animal host defense peptides (HDPs) which uniquely evolved to protect the hosts have been shown to have antiviral properties (
 <xref rid="B33" ref-type="bibr">Shartouny and Jacob, 2018</xref>). However, although natural HDPs show excellent therapeutic potential, still, certain factors limit their clinical application (
 <xref rid="B7" ref-type="bibr">Boto et al., 2018</xref>). A better understanding of HDPs has enhanced the development of natural peptides derived analogs with improved pharmacological properties and reduced side effects (
 <xref rid="B14" ref-type="bibr">Fjell et al., 2011</xref>; 
 <xref rid="B24" ref-type="bibr">Jin et al., 2016</xref>; 
 <xref rid="B7" ref-type="bibr">Boto et al., 2018</xref>).
</p>
